Stance Capital LLC Makes New $3.10 Million Investment in CVS Health Corporation $CVS

Stance Capital LLC acquired a new stake in CVS Health Corporation (NYSE:CVS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,048 shares of the pharmacy operator’s stock, valued at approximately $3,099,000. CVS Health makes up 1.1% of Stance Capital LLC’s portfolio, making the stock its 23rd largest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd boosted its stake in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. bought a new stake in shares of CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the fourth quarter worth $28,000. Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health during the fourth quarter worth $28,000. Finally, Ares Financial Consulting LLC purchased a new position in CVS Health during the fourth quarter valued at $29,000. Institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on CVS. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. UBS Group raised their price objective on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Morgan Stanley lifted their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Barclays increased their price target on CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $100.68.

Insider Buying and Selling at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 over the last ninety days. 0.85% of the stock is owned by insiders.

CVS Health Trading Down 0.1%

Shares of CVS stock opened at $98.26 on Friday. The company has a market cap of $125.38 billion, a PE ratio of 43.29, a price-to-earnings-growth ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The stock’s 50 day simple moving average is $89.31 and its two-hundred day simple moving average is $81.48. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the previous year, the business earned $2.25 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.